#NICA2020 Has Been Postponed
During this unprecedented time, our focus remains on continuity of care and safety. After considerable deliberation, we have decided to postpone NICA’s 2020 meeting until June of 2021 due to the COVID-19 pandemic. Although this was a difficult decision, the health and safety of our attendees, faculty, and exhibitors remains our top priority. This is not a risk we are willing to take.
The 2021 meeting will take place June 25-26, 2021 at the same venue, the Dallas Marriott Downtown, in Dallas, Texas.
Both attendees and exhibitors who had already registered should have received a message from our Executive Director outlining how we are proceeding through this transition and options for existing registrations. Please note that everyone will need to re-register once registration opens in December 2020 in order to attend the 2021 meeting.
In the meantime…
Here's a Look Back at NICA's Inaugural Meeting
At the 2019 meeting, NICA welcomed over 500 leaders and professionals in the infusion industry to its inaugural meeting. During the two-day event, attendees participated in thirteen breakout sessions lead by members of leadership from some of the largest and most reputable organizations in the industry. Attendees also had the opportunity to network with peers and colleagues during educational dinner programs, complimentary receptions, and exhibit hall hours.
Click Below to Receive 2021 Meeting Updates
We Look Forward to Seeing You in 2021!
National Infusion Center Association (NICA) is a nonprofit organization founded to improve patient access to in-office infusion. Since its inception in 2010, NICA has worked to support infusion patients and their office-based care settings through advocacy, education and resource development. As the only organization dedicated to preserving patient access to provider-administered parenteral medications in more economical and accessible alternatives to hospital sites of care, NICA strives to: connect infusion providers and patients with the resources they need; collaborate with stakeholders to develop all-win solutions; and advocate on behalf of this historically underrepresented patient group.